Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Xu-Hua Guan(Hubei Provincial Center for Disease Control and Prevention), Yu-Hua Li(National Institutes for Food and Drug Control), Jian-Ying Huang(Wuhan University), Tao Jiang(Institute of Microbiology), Li-Hua Hou(Academy of Military Medical Sciences), Jingxin Li(Jiangsu Provincial Center for Disease Control and Prevention), Bei-Fang Yang(Hubei Provincial Center for Disease Control and Prevention), Ling Wang(National Institutes for Food and Drug Control), Wen-Juan Wang(Jiangsu Provincial Center for Disease Control and Prevention), Shi-Po Wu(Academy of Military Medical Sciences), Zhao Wang(Hubei Provincial Center for Disease Control and Prevention), Xiao-Hong Wu(National Institutes for Food and Drug Control), Junjie Xu(Academy of Military Medical Sciences), Zhe Zhang(Academy of Military Medical Sciences), Si-Yue Jia(Jiangsu Provincial Center for Disease Control and Prevention), Busen Wang(Academy of Military Medical Sciences), Yi Hu(Institute of Microbiology), Jing‐Jing Liu(National Institutes for Food and Drug Control), Jun Zhang(Academy of Military Medical Sciences), Xiao-Ai Qian(Hubei Provincial Center for Disease Control and Prevention), Qiong Li(Hubei Provincial Center for Disease Control and Prevention), Hong-Xing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Hu-Dachuan Jiang(Jiangsu Provincial Center for Disease Control and Prevention), Peng Deng(Hubei Provincial Center for Disease Control and Prevention), Jin-Bo Gou(CanSino (China)), Xue-Wen Wang(Wuhan University), Xue-Wen Wang(Wuhan University), Xinghuan Wang(Academy of Military Medical Sciences), Xinghuan Wang(Wuhan University), Wei Chen(Academy of Military Medical Sciences)
Cited by 1,292Open Access